1. Home
  2. CRDL vs SGC Comparison

CRDL vs SGC Comparison

Compare CRDL & SGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

N/A

Current Price

$0.97

Market Cap

226.6M

Sector

Health Care

ML Signal

N/A

Logo Superior Group of Companies Inc.

SGC

Superior Group of Companies Inc.

N/A

Current Price

$13.47

Market Cap

214.8M

ML Signal

N/A

Company Overview

Basic Information
Metric
CRDL
SGC
Founded
2017
1920
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
226.6M
214.8M
IPO Year
2017
1994

Fundamental Metrics

Financial Performance
Metric
CRDL
SGC
Price
$0.97
$13.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
2
Target Price
$8.55
★ $18.00
AVG Volume (30 Days)
★ 764.3K
22.1K
Earning Date
11-20-2026
11-09-2026
Dividend Yield
N/A
★ 4.21%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.14
Revenue
N/A
★ $566,184,000.00
Revenue This Year
N/A
$3.02
Revenue Next Year
N/A
$3.83
P/E Ratio
★ N/A
$100.57
Revenue Growth
N/A
★ 0.09
52 Week Low
$0.88
$8.30
52 Week High
$2.34
$14.59

Technical Indicators

Market Signals
Indicator
CRDL
SGC
Relative Strength Index (RSI) 28.32 55.19
Support Level $0.94 $11.52
Resistance Level $1.10 $13.66
Average True Range (ATR) 0.06 0.63
MACD 0.00 0.07
Stochastic Oscillator 20.33 63.54

Price Performance

Historical Comparison
CRDL
SGC

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

About SGC Superior Group of Companies Inc.

Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.

Share on Social Networks: